4.7 Article

Pharmacogenomics in clinical trials: an overview

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Ethics

Ethical considerations about the collection of biological samples for genetic analysis in clinical trials

Ines Galende-Dominguez et al.

Summary: Progress in precision medicine is achieved through clinical trials using genetic biomarkers to guide patient stratification and assign treatment or control groups. Genetic analysis of biomarkers is essential, involving the study of biological samples from donor patients. However, it is common to introduce purposes beyond the trial's objectives, leading to potential risks of data misuse and re-identification of sample donors. Therefore, genetic analysis should be restricted to the trial's main objectives or well-justified goals.

RESEARCH ETHICS (2023)

Article Pharmacology & Pharmacy

Healthcare professionals' knowledge, confidence and perceptions of pharmacogenomics in primary care and pain management

Matthew P. Behr et al.

Summary: This study aimed to assess the knowledge, confidence, and perceptions of healthcare professionals at Brigham and Women's Hospital specializing in primary care and pain management regarding clinical pharmacogenomics (PGx). A 25-question online survey was distributed to 328 clinicians, and the results showed that respondents had limited experience and awareness of PGx resources. While believing in the utility of PGx to improve patient outcomes, many lacked confidence in applying PGx results to their practice. This study highlights the need for more clinician education on the appropriate utilization of PGx in primary care and pain management.

PHARMACOGENOMICS (2023)

Article Medicine, General & Internal

Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Randomized Clinical Trial

Cornelis F. Vos et al.

Summary: This randomized clinical trial found that pharmacogenetics-informed treatment with tricyclic antidepressants (TCAs) resulted in faster attainment of therapeutic drug concentrations and potentially fewer adverse effects in patients with unipolar major depressive disorder. However, the evidence for the clinical benefit of pharmacogenetics-informed treatment with TCAs is still limited.

JAMA NETWORK OPEN (2023)

Article Oncology

Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted

Tristan M. Sissung et al.

Summary: This article analyzes phase I clinical studies in oncology with a focus on pharmacogenetics. The findings suggest that current studies have small sample sizes, evaluate a limited number of genetic variants, and lack sufficient justification for pharmacogenetic hypotheses. Future studies should consider population heterogeneity and other confounding factors to optimize the design of phase I clinical trials and answer important scientific questions.

CANCERS (2022)

Review Pharmacology & Pharmacy

Pharmacogenomic Testing and Depressive Symptom Remission: A Systematic Review and Meta-Analysis of Prospective, Controlled Clinical Trials

Lisa C. Brown et al.

Summary: This study systematically reviewed and meta-analyzed the association between PGx-guided antidepressant therapy and depressive symptom remission in MDD patients. The results suggest that PGx-guided antidepressant therapy is modestly but significantly associated with an increase in depressive symptom remission in adults with MDD.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)

Article Public, Environmental & Occupational Health

An overview of Personalized Medicine landscape and policies in the European Union

F. Beccia et al.

Summary: There are multiple policies related to Personalized Medicine at both the European Union and member states level, aiming to improve public health, promote the implementation of Personalized Medicine, and focus on disease prevention and patient engagement. The establishment of an integrated regulatory framework is essential for realizing the opportunities of Personalized Medicine and promoting international collaboration.

EUROPEAN JOURNAL OF PUBLIC HEALTH (2022)

Review Cardiac & Cardiovascular Systems

Pharmacogenetics to guide cardiovascular drug therapy

Julio D. Duarte et al.

Summary: This Review examines the evidence supporting pharmacogenetic testing in cardiovascular medicine, including data from clinical trials, and provides examples of clinical implementation of genotype-guided cardiovascular therapies. Opportunities for future growth of the field are also discussed.

NATURE REVIEWS CARDIOLOGY (2021)

Article Pharmacology & Pharmacy

An Evidence-Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine

Michelle Whirl-Carrillo et al.

Summary: Clinical annotations in PharmGKB summarize the association between variant-drug pairs and are assigned a level of evidence. To ensure consistency and transparency, a scoring system has been developed to automate LOE assignment. This system improves the quality and reliability of clinical annotations.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2021)

Article Medicine, General & Internal

STrengthening the Reporting Of Pharmacogenetic Studies: Development of the STROPS guideline

Marty Chaplin et al.

PLOS MEDICINE (2020)

Article Medicine, General & Internal

A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI

Daniel M. F. Claassens et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Article Cardiac & Cardiovascular Systems

Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes The PHARMCLO Trial

Francesca Maria Notarangelo et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)

Review Genetics & Heredity

Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention

Kalliopi Gerogianni et al.

MOLECULAR DIAGNOSIS & THERAPY (2018)

Article Genetics & Heredity

Multidisciplinary model to implement pharmacogenomics at the point of care

Pedro J. Caraballo et al.

GENETICS IN MEDICINE (2017)

Article Pharmacology & Pharmacy

Clinicians' perceptions of pharmacogenomics use in psychiatry

Christopher Yi Wen Chan et al.

PHARMACOGENOMICS (2017)

Review Genetics & Heredity

Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?

M. Verbelen et al.

PHARMACOGENOMICS JOURNAL (2017)

Review Biochemistry & Molecular Biology

Severe Cutaneous Adverse Reactions: The Pharmacogenomics from Research to Clinical Implementation

Shih-Chi Su et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)

Article Economics

Through a Glass Darkly: Economics and Personalised Medicine

Alan Haycox et al.

PHARMACOECONOMICS (2014)

Review Genetics & Heredity

Pharmacogenomics in oncology care

Kelly K. Filipski et al.

FRONTIERS IN GENETICS (2014)

Review Pharmacology & Pharmacy

Pharmacogenomics in early-phase clinical development

Tal Burt et al.

PHARMACOGENOMICS (2013)

Article Genetics & Heredity

Primary care physicians' knowledge of and experience with pharmacogenetic testing

S. B. Haga et al.

CLINICAL GENETICS (2012)

Article Pharmacology & Pharmacy

Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project

J. M. Pulley et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)

Editorial Material Pharmacology & Pharmacy

Pharmacogenomics Knowledge for Personalized Medicine

M. Whirl-Carrillo et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)

Article Genetics & Heredity

Attitudes of Health Care Professionals Toward Pharmacogenetic Testing

Nathalie K. Zgheib et al.

MOLECULAR DIAGNOSIS & THERAPY (2011)

Article Cardiac & Cardiovascular Systems

The SLCO1B1*5 Genetic Variant Is Associated With Statin-Induced Side Effects

Deepak Voora et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)

Editorial Material Medicine, General & Internal

Pharmacogenomic biomarkers for prediction of severe adverse drug reactions

Magnus Ingelman-Sundberg

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Review Pharmacology & Pharmacy

Pharmacogenomics of psychiatric disorders

D Pickar et al.

TRENDS IN PHARMACOLOGICAL SCIENCES (2001)